Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some general pharmacology and dosing-time statements are consistent with the label, but multiple quantitative bioavailability/food/drug-effect and interaction magnitude claims are not supported by the provided prescribing information excerpts, indicating substantial gaps in accuracy.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
Section 12.1 (mechanism) and Sections 1.2/14.2 (reduces total-C/LDL-C/TG; lipid-altering therapy).
Lipitor works by inhibiting the production of cholesterol in the liver, thereby reducing the amount of cholesterol in the bloodstream.
Section 12.1: selective, competitive inhibitor of HMG-CoA reductase; reduces total-C/LDL-C and other lipid effects.
Lipitor can be taken with or without food.
Section 2.1: can be administered once daily at any time of day, with or without food; Section 12.3: food decreases rate/extent but LDL-C reduction similar with or without food.
Unsupported Statements
Taking Lipitor with a meal increases atorvastatin bioavailability by 30% compared to taking it on an empty stomach.
Provided label excerpts state food decreases rate and extent and that LDL-C reduction is similar, but do not provide any 30% bioavailability increase figure.
The manufacturer’s instructions recommend taking Lipitor with a full glass of water to ensure proper absorption.
No provided label excerpt includes instructions to take with a full glass of water.
Caffeine can decrease the absorption of atorvastatin by 20%.
No provided label excerpt mentions caffeine or a caffeine-atorvastatin absorption effect.
Grapefruit juice can increase the levels of atorvastatin in the blood by 50%.
Provided label excerpt for grapefruit juice indicates increased plasma concentrations, especially with excessive intake (>1.2 L/day), but does not quantify a 50% increase.
Contradictions
Important Omissions
Details of clinically relevant grapefruit juice guidance (e.g., emphasis on excessive consumption threshold) and other specific interaction risk management (e.g., dosing limits with strong CYP3A4 inhibitors) when making interaction magnitude claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Quantitative interaction claims (bioavailability increase, caffeine decrease, grapefruit 50% increase) are unsupported by the provided label excerpts; while this does not establish a direct contraindication, it could mislead about magnitude of interaction risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several quantitative absorption/bioavailability and interaction magnitude claims are not supported by the provided labeling excerpts (meal bioavailability +30%, caffeine -20%, grapefruit juice +50%, full glass of water).
Suggested Improvement
Remove or rephrase unsupported quantitative claims and align interaction statements to the label language provided (e.g., grapefruit juice can increase plasma concentrations, especially with excessive consumption >1.2 L/day; food can be used with/without food with similar LDL-C reduction).